- Home
- KLAR vs MIRM Comparison
KLAR vs MIRM Comparison
Compare KLAR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLAR | MIRM |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United Kingdom | United States |
| Employees | 2831 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.7B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | KLAR | MIRM |
|---|---|---|
| Price | $17.62 | $101.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | $38.00 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 5.3M | 599.7K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $28.56 | $26.22 |
| Revenue Next Year | $19.93 | $22.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.06 | $47.89 |
| 52 Week High | $47.48 | $114.99 |
Technical Indicators
Market Signals| Indicator | KLAR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 56.56 |
| Support Level | $12.77 | $87.93 |
| Resistance Level | $18.55 | $107.51 |
| Average True Range (ATR) | 0.91 | 4.33 |
| MACD | -0.10 | 0.50 |
| Stochastic Oscillator | 72.77 | 77.41 |
Price Performance
Historical ComparisonAbout KLAR Klarna Group plc Ordinary Shares
Klarna Group PLC is a technology-driven payments company, with operations spanning multiple countries. It connects consumers and merchants with comprehensive payment solutions and tailored advertising solutions, both online and offline. Its payment solutions provide consumers with more control and flexibility over their payments. It is a digital bank and flexible payments provider building the next-generation AI-powered commerce network.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.